cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.25668818
title: Genome-wide analysis of the <i>MATE</i> gene family and expression analysis of subfamily III genes in response to aluminium toxicity in pineapple

description: Pineapple has strong adaptability to acidic soil and has become a significant economic fruit crop in the tropics and subtropics. The multidrug and toxin compound extrusion (MATE) gene family plays crucial roles in plant growth, development and responses to adverse stresses, especially in acidic soils. In this study, forty-two <i>AcMATE</i> genes were identified and classified into six subfamilies based on phylogenetic analysis. The chromosomal distribution, physical characteristics, phylogenetic relationships, and gene and protein structures of pineapple <i>MATE</i> gene family members were systematically analysed. Our results showed that six <i>AcMATE</i> genes can be further clustered into subfamily III with similar conserved motifs and exon-intron patterns, and are unevenly distributed on four pineapple chromosomes. Citrate exuding motif (CEM) was present in all six AcMATE proteins of subfamily III. Finally, quantitative real-time PCR experiments indicated that subfamily III <i>AcMATE</i> genes were highly expressed in roots and distinctly upregulated under Al stresses. In conclusion, our study illustrated that the <i>AcMATE</i> genes of subfamily III may function as an Al-induced citrate transporter in alleviating Al toxicity to adapt acidic soil in pineapple.
DOI: 10.6084/m9.figshare.25668818.v1
title: Genome-wide analysis of the <i>MATE</i> gene family and expression analysis of subfamily III genes in response to aluminium toxicity in pineapple

description: Pineapple has strong adaptability to acidic soil and has become a significant economic fruit crop in the tropics and subtropics. The multidrug and toxin compound extrusion (MATE) gene family plays crucial roles in plant growth, development and responses to adverse stresses, especially in acidic soils. In this study, forty-two <i>AcMATE</i> genes were identified and classified into six subfamilies based on phylogenetic analysis. The chromosomal distribution, physical characteristics, phylogenetic relationships, and gene and protein structures of pineapple <i>MATE</i> gene family members were systematically analysed. Our results showed that six <i>AcMATE</i> genes can be further clustered into subfamily III with similar conserved motifs and exon-intron patterns, and are unevenly distributed on four pineapple chromosomes. Citrate exuding motif (CEM) was present in all six AcMATE proteins of subfamily III. Finally, quantitative real-time PCR experiments indicated that subfamily III <i>AcMATE</i> genes were highly expressed in roots and distinctly upregulated under Al stresses. In conclusion, our study illustrated that the <i>AcMATE</i> genes of subfamily III may function as an Al-induced citrate transporter in alleviating Al toxicity to adapt acidic soil in pineapple.
DOI: 10.6084/m9.figshare.25909456
title: Nano-TiO<sub>2</sub> enhanced fruit storage chambers: unveiling the potential for prolonging banana shelf life

description: This manuscript focuses on the development of Fruit Storage Chamber (FSC) equipped with nano-TiO<sub>2</sub> and its modular prototype to improve the value of bamboo-based FSC by its photocatalytic and feasibility aspects. Its effects on fruit shelf life and ripening-related gene expression were studied. Cavendish bananas were stored in FSC equipped with nano-TiO<sub>2</sub> and modular FSC for treatments. Relative expression level of ethylene biosynthesis-related (<i>MaACS1</i>, <i>MaACO1</i>) and polyphenol oxidase (<i>MaPPO4</i>, <i>MaPPO5</i>) genes were examined. The dynamics of ripening variables throughout the storage period were illustrated in regression lines, followed with hypothesis testing. Banana quantity showed no significant changes upon storage in FSC equipped with nano-TiO<sub>2</sub>. Physical appearance indicated a ripening delay of up to two days on nano-TiO<sub>2</sub> treatments compared to control. Ethylene production rate and ethylene related gene expression were not significantly altered. Browning index was more maintained in nano-TiO<sub>2</sub> treated samples, supported by the observation of slower increase of <i>MaPPO4</i> and <i>MaPPO5</i> relative expressions compared to control. The findings highlight the suppression of fruit ripening related gene expression and the maintenance of fruit quality in treated samples compared to control, indicating the potential use of nano-TiO<sub>2</sub> to prolong banana shelf life.
DOI: 10.6084/m9.figshare.25909456.v1
title: Nano-TiO<sub>2</sub> enhanced fruit storage chambers: unveiling the potential for prolonging banana shelf life

description: This manuscript focuses on the development of Fruit Storage Chamber (FSC) equipped with nano-TiO<sub>2</sub> and its modular prototype to improve the value of bamboo-based FSC by its photocatalytic and feasibility aspects. Its effects on fruit shelf life and ripening-related gene expression were studied. Cavendish bananas were stored in FSC equipped with nano-TiO<sub>2</sub> and modular FSC for treatments. Relative expression level of ethylene biosynthesis-related (<i>MaACS1</i>, <i>MaACO1</i>) and polyphenol oxidase (<i>MaPPO4</i>, <i>MaPPO5</i>) genes were examined. The dynamics of ripening variables throughout the storage period were illustrated in regression lines, followed with hypothesis testing. Banana quantity showed no significant changes upon storage in FSC equipped with nano-TiO<sub>2</sub>. Physical appearance indicated a ripening delay of up to two days on nano-TiO<sub>2</sub> treatments compared to control. Ethylene production rate and ethylene related gene expression were not significantly altered. Browning index was more maintained in nano-TiO<sub>2</sub> treated samples, supported by the observation of slower increase of <i>MaPPO4</i> and <i>MaPPO5</i> relative expressions compared to control. The findings highlight the suppression of fruit ripening related gene expression and the maintenance of fruit quality in treated samples compared to control, indicating the potential use of nano-TiO<sub>2</sub> to prolong banana shelf life.
DOI: 10.6084/m9.figshare.24884552
title: Analgesic onset and efficacy of a fast-acting formulation of acetaminophen in a postoperative dental impaction pain model

description: Speed of onset can be critical to an analgesic’s efficacy treating acute pain. To enhance onset, a new oral acetaminophen formulation intended to be fast acting was developed. Two studies evaluated the analgesic onset, efficacy, and safety of this fast-acting acetaminophen (FA-acetaminophen) tablet relative to commercial acetaminophen caplets (ES-acetaminophen) and commercial ibuprofen liquid-filled gelatin capsules (LG-ibuprofen). Two single-center, single-dose, inpatient, randomized, double-blind, triple-dummy, placebo-controlled, parallel group design clinical trials were conducted using the postoperative dental impaction pain model. Subjects were healthy men and women aged 17–50 years experiencing moderate-to-severe pain after surgical extraction of at least three impacted third molars. In both studies, four treatment groups were evaluated: 1,000 mg acetaminophen as two 500 mg FA-acetaminophen tablets, 1,000 mg as two 500 mg ES-acetaminophen caplets, 400 mg ibuprofen as two 200 mg LG-ibuprofen capsules, and placebo. To maintain blinding, each subject received six units of study medication. Times to confirmed perceptible pain relief (TCPR) and meaningful pain relief (TMPR) were obtained using the double-stopwatch method. Pain intensity and relief were measured over 6 h following drug administration using a 0–10 numerical rating scale. Time to use of rescue medication (naproxen sodium) and subject global evaluations of study medications at 6 h were collected. Pharmacokinetic blood sampling and safety assessments were performed. Studies 1 and 2 enrolled 240 and 420 subjects, respectively. No clinically important differences among treatment groups were observed for any demographic or baseline characteristics. Efficacy results showed all active treatments statistically superior to placebo. In Study 1, TCPR was statistically significantly shorter for FA-acetaminophen compared to ES-acetaminophen and LG-ibuprofen. In Study 2, no statistically significant differences in TCPR were noted across the active treatment groups. In Study 1, FA-acetaminophen 1,000 mg provided significantly shorter TMPR compared with LG-ibuprofen but not compared with ES-acetaminophen. In Study 2, no significant differences in TMPR were noted across the active treatment groups. In both Study 1 and 2 at 15 min after administration of study drug, PID and PAR scores were greater for FA-acetaminophen than LG-ibuprofen. Both studies suggested FA-acetaminophen had faster onset of action compared to ES-acetaminophen and LG-Ibuprofen. In light of the difference in TCPR and TMPR results between Study 1 and 2, an additional study is needed to further investigate time to analgesic onset of FA-acetaminophen compared with ES-acetaminophen and LG-Ibuprofen. Study 1: NCT02735122; Study 2: NCT03224403
DOI: 10.6084/m9.figshare.24884552.v2
title: Analgesic onset and efficacy of a fast-acting formulation of acetaminophen in a postoperative dental impaction pain model

description: Speed of onset can be critical to an analgesic’s efficacy treating acute pain. To enhance onset, a new oral acetaminophen formulation intended to be fast acting was developed. Two studies evaluated the analgesic onset, efficacy, and safety of this fast-acting acetaminophen (FA-acetaminophen) tablet relative to commercial acetaminophen caplets (ES-acetaminophen) and commercial ibuprofen liquid-filled gelatin capsules (LG-ibuprofen). Two single-center, single-dose, inpatient, randomized, double-blind, triple-dummy, placebo-controlled, parallel group design clinical trials were conducted using the postoperative dental impaction pain model. Subjects were healthy men and women aged 17–50 years experiencing moderate-to-severe pain after surgical extraction of at least three impacted third molars. In both studies, four treatment groups were evaluated: 1,000 mg acetaminophen as two 500 mg FA-acetaminophen tablets, 1,000 mg as two 500 mg ES-acetaminophen caplets, 400 mg ibuprofen as two 200 mg LG-ibuprofen capsules, and placebo. To maintain blinding, each subject received six units of study medication. Times to confirmed perceptible pain relief (TCPR) and meaningful pain relief (TMPR) were obtained using the double-stopwatch method. Pain intensity and relief were measured over 6 h following drug administration using a 0–10 numerical rating scale. Time to use of rescue medication (naproxen sodium) and subject global evaluations of study medications at 6 h were collected. Pharmacokinetic blood sampling and safety assessments were performed. Studies 1 and 2 enrolled 240 and 420 subjects, respectively. No clinically important differences among treatment groups were observed for any demographic or baseline characteristics. Efficacy results showed all active treatments statistically superior to placebo. In Study 1, TCPR was statistically significantly shorter for FA-acetaminophen compared to ES-acetaminophen and LG-ibuprofen. In Study 2, no statistically significant differences in TCPR were noted across the active treatment groups. In Study 1, FA-acetaminophen 1,000 mg provided significantly shorter TMPR compared with LG-ibuprofen but not compared with ES-acetaminophen. In Study 2, no significant differences in TMPR were noted across the active treatment groups. In both Study 1 and 2 at 15 min after administration of study drug, PID and PAR scores were greater for FA-acetaminophen than LG-ibuprofen. Both studies suggested FA-acetaminophen had faster onset of action compared to ES-acetaminophen and LG-Ibuprofen. In light of the difference in TCPR and TMPR results between Study 1 and 2, an additional study is needed to further investigate time to analgesic onset of FA-acetaminophen compared with ES-acetaminophen and LG-Ibuprofen. Study 1: NCT02735122; Study 2: NCT03224403
DOI: 10.6084/m9.figshare.24884552.v1
title: Analgesic onset and efficacy of a fast-acting formulation of acetaminophen in a postoperative dental impaction pain model

description: Speed of onset can be critical to an analgesic’s efficacy treating acute pain. To enhance onset, a new oral acetaminophen formulation intended to be fast acting was developed. Two studies evaluated analgesic onset, efficacy, and safety of this fast-acting acetaminophen (FA-acetaminophen) tablet relative to commercial acetaminophen caplets (ES-acetaminophen) and commercial ibuprofen liquid-filled gelatin capsules (LG-ibuprofen). Two single-center, single-dose, inpatient, randomized, double-blind, triple-dummy, placebo-controlled, parallel group design clinical trials were conducted using the postoperative dental impaction pain model. Subjects were healthy men and women aged 17 to 50 years experiencing moderate-to-severe pain after surgical extraction of at least 3 impacted third molars. In both studies, 4 treatment groups were evaluated: 1000 mg acetaminophen as two 500 mg FA-acetaminophen tablets, 1000 mg as two 500 mg ES-acetaminophen caplets, 400 mg ibuprofen as two 200 mg LG-ibuprofen capsules, and placebo. To maintain blinding, each subject received 6 units of study medication. Times to confirmed perceptible pain relief (TCPR) and meaningful pain relief (TMPR) were obtained using the double-stopwatch method. Pain intensity and relief were measured over 6 hours following drug administration using a 0-10 numerical rating scale. Time to use of rescue medication (naproxen sodium) and subject global evaluations of study medications at 6 hours were collected. Pharmacokinetic blood sampling and safety assessments were performed. Studies 1 and 2 enrolled 240 and 420 subjects, respectively. No clinically important differences among treatment groups were observed for any demographic or baseline characteristics. Efficacy results showed all active treatments statistically superior to placebo. In Study 1, TCPR was statistically significantly shorter for FA-acetaminophen compared to ES-acetaminophen and LG-ibuprofen. In Study 2, no statistically significant differences in TCPR were noted across the active treatment groups. In Study 1, FA-acetaminophen 1000 mg provided significantly shorter TMPR compared with LG-ibuprofen but not compared with ES-acetaminophen. In Study 2, no significant differences in TMPR were noted across the active treatment groups. In both Study 1 and 2 at 15 min after administration of study drug, PID and PAR scores were greater for FA-acetaminophen than LG-ibuprofen. Both studies suggested FA-acetaminophen had faster onset of action compared to ES-acetaminophen and LG-Ibuprofen. In light of the difference in TCPR and TMPR results between Study 1 and 2, an additional study is needed to further investigate time to analgesic onset of FA-acetaminophen compared with ES-acetaminophen and LG-Ibuprofen. Study 1: NCT02735122; Study 2: NCT03224403
DOI: 10.6084/m9.figshare.24599249
title: Effect of preoperative moderate-dose statin and duration on acute kidney injury after cardiac surgery: a retrospective cohort study

description: The impact of preoperative statin use on postoperative acute kidney injury (AKI) is uncertain. We aimed to examine the association of statin therapy before cardiac surgery with postoperative AKI. The retrospective cohort study consisted of 1581 patients undergoing cardiac surgery. Postoperative AKI were identified by the modified KDIGO definition. Propensity-score matching was employed to control for selection bias, and logistic regression was used to control for confounders. Subgroup and interaction analyses were performed to evaluate the robustness of the findings. The overall incidence of postoperative AKI and severe AKI were 42.19% and 12.27%, respectively. Preoperative moderate-dose statin was significantly associated with a reduced incidence of postoperative AKI (28.9% vs 43.0%, OR (95%CI): 0.54 (0.38, 0.77), <i>p</i> &lt; 0.001) and severe AKI (6.9% vs 13.7%, OR (95%CI): 0.46 (0.26, 0.83), <i>p</i> = 0.009). The beneficial effect on postoperative AKI persisted after adjusting for major confounding factors (OR (95%CI): 0.47 (0.34, 0.66)). Decreased risk of postoperative AKI was observed in patients with preoperative statin duration of 7 ∼ 14 days (OR (95%CI): 0.41 (0.25, 0.65)) and over 14 days (OR (95%CI): 0.43 (0.28, 0.65)), but not in those with preoperative statin duration of &lt;7 days. Similar favorable effects were noted in most subgroup patients, except for those with high-risk factors such as diabetes mellitus, previous congestive cardiac failure, arrhythmia, preoperative ACEI/ARB, aortic cross-clamping or IABP. Preoperative moderate-dose statin was significantly related to a decreased risk of postoperative AKI, especially in patients who received statins for a longer duration. Further large-scale multicenter randomized controlled trials are needed to ascertain the impact of statin dose, duration, and timing on postoperative AKI in cardiac surgery patients.
DOI: 10.6084/m9.figshare.24599249.v1
title: Effect of preoperative moderate-dose statin and duration on acute kidney injury after cardiac surgery: a retrospective cohort study

description: The impact of preoperative statin use on postoperative acute kidney injury (AKI) is uncertain. We aimed to examine the association of statin therapy before cardiac surgery with postoperative AKI. The retrospective cohort study consisted of 1581 patients undergoing cardiac surgery. Postoperative AKI were identified by the modified KDIGO definition. Propensity-score matching was employed to control for selection bias, and logistic regression was used to control for confounders. Subgroup and interaction analyses were performed to evaluate the robustness of the findings. The overall incidence of postoperative AKI and severe AKI were 42.19% and 12.27%, respectively. Preoperative moderate-dose statin was significantly associated with a reduced incidence of postoperative AKI (28.9% vs 43.0%, OR (95%CI): 0.54 (0.38, 0.77), <i>p</i> &lt; 0.001) and severe AKI (6.9% vs 13.7%, OR (95%CI): 0.46 (0.26, 0.83), <i>p</i> = 0.009). The beneficial effect on postoperative AKI persisted after adjusting for major confounding factors (OR (95%CI): 0.47 (0.34, 0.66)). Decreased risk of postoperative AKI was observed in patients with preoperative statin duration of 7 ∼ 14 days (OR (95%CI): 0.41 (0.25, 0.65)) and over 14 days (OR (95%CI): 0.43 (0.28, 0.65)), but not in those with preoperative statin duration of &lt;7 days. Similar favorable effects were noted in most subgroup patients, except for those with high-risk factors such as diabetes mellitus, previous congestive cardiac failure, arrhythmia, preoperative ACEI/ARB, aortic cross-clamping or IABP. Preoperative moderate-dose statin was significantly related to a decreased risk of postoperative AKI, especially in patients who received statins for a longer duration. Further large-scale multicenter randomized controlled trials are needed to ascertain the impact of statin dose, duration, and timing on postoperative AKI in cardiac surgery patients.
DOI: 10.6084/m9.figshare.24756924.v1
title: The association between influenza vaccine effectiveness and egg-based manufacturing technology: literature review and US expert consensus

description: Influenza is associated with significant disease burden in the US and is currently best controlled by vaccination programs. Influenza vaccine effectiveness (VE) is low and may be reduced by several factors, including egg adaptations. Although non-egg-based influenza vaccines reportedly have greater VE in egg-adapted seasons, evidence for egg adaptations’ reduction of VE is indirect and dissociated, apart from two previous European consensuses. This study replicated the methodology used in a 2020 literature review and European consensus, providing an updated review and consensus opinion of 10 US experts on the evidence for a mechanistic basis for reduction of VE due to egg-based manufacturing methods. A mechanistic basis was assumed if sufficient evidence was found for underlying principles proposed to give rise to such an effect. Evidence for each principle was brought forward from the 2020 review and identified here by structured literature review and expert panel. Experts rated the strength of support for each principle and a mechanistic basis for reduction of VE due to egg-based influenza vaccine manufacture in a consensus method (consensus for strong/very strong evidence = ≥ 3.5 on 5-point Likert scale). Experts assessed 251 references (from previous study: 185; this study: 66). The majority of references for all underlying principles were rated as strong or very strong supporting evidence (52–86%). Global surveillance, WHO candidate vaccine virus selection, and manufacturing stages involving eggs were identified as most likely to impact influenza VE. After review of extensive evidence for reduction of VE due to egg-based influenza vaccine manufacture, influenza experts in the US joined those in Europe in unanimous agreement for a mechanistic basis for the effect. Vaccine providers and administrators should consider use of non-egg-based influenza vaccine manufacture to reduce the risk of egg adaptations and likely impact on VE.
DOI: 10.6084/m9.figshare.24865121
title: Associations of serum uric acid levels and anthropometric parameters with non-alcoholic fatty liver disease in healthy individuals: innovative insights from a cross-sectional study

description: Non-alcoholic fatty liver disease (NAFLD is a spectrum of liver disease with a rising prevalence, ranging from simple steatosis to steatohepatitis and cirrhosis, where a significant minority face potential complications. Determining the predictive markers plays a crucial role. This study examined the relationship between serum uric acid (SUA) levels and NAFLD in healthy individuals and identified potential other predictors. A cohort of 2162 healthy participants attending routine check-up visits between February 2021 and May 2023 were included. Participants underwent abdominal ultrasound, uric acid measurements, and anthropometric assessments by TANITA. NAFLD was graded using a "hepatic steatosis score." Statistical analysis included nonparametric tests, chi-squared tests, Fisher’s exact test, ROC curve analysis, and logistic regression. The median age was 45 years (range:18-65). 1017 were male, and 1145 were female. Among the participants, 53.9%, 26.3%, 17.9%, and 1.9% exhibited Grade 0, 1, 2, and 3 hepatic steatosis, respectively. ROC analysis showed 80.0% sensitivity and 78.8% specificity for detecting grade 2 or higher hepatic steatosis with a cutoff value of 5.21 mg/dl of SUA (AUC = 0.82, <i>p</i> &lt; 0.001, 95%CI 0.79-0.84). There were significant associations between elevated uric acid levels and NAFLD. Participants with higher body fat percentages, BMI values, and waist-to-hip ratios also demonstrated an increased prevalence of steatosis. Gender significantly influenced liver steatosis, with males exhibiting higher grades compared to females. Logistic regression analysis highlighted positive associations between NAFLD and body fat percentage, waist-to-hip ratio, and uric acid levels. Each unit increase in uric acid levels corresponded to a 2.5-fold increase in the odds of NAFLD (<i>p</i> &lt; 0.001, 95% CI = 2.20-2.84). Our findings suggest a significant relationship between serum uric acid levels and NAFLD in healthy individuals. Elevated uric acid levels, in conjunction with other anthropometric parameters, may serve as potential predictive markers for NAFLD.